BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 11
• 12
• 13
• 14
• 15
• 16
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29

• 

  Policy

  AstraZeneca Case Leads Off Busy Year of Challenges to Medicare Drug Pricing Law

  The first hearing on a potential injunction came the day before CMS is to release pricing proposals on 10 drugs.

  February 1, 2024

   · 

  5 min read

   · 

  Neil Versel
• 

  Drug Development

  Vertex’s Non-Opioid Pain Drug Failed to Beat Vicodin: Can It Be Improved On?

  Positive Phase III results for VX-548 could signal a new chapter in the fight against opioid addiction, but experts say there is still room to do better.

  February 1, 2024

   · 

  3 min read

   · 

  Heather McKenzie
• 

  Policy

  IRA’s Impact on Industry Revenues, R&D Will Be Modest: Study

  The Inflation Reduction Act’s Drug Price Negotiation Program will erode only a small portion of global biopharma revenues and is unlikely to cause significant cuts to research and development, find researchers.

  February 1, 2024

   · 

  3 min read

   · 

  Tristan Manalac
• 

  Business

  Sanofi Hit with $600M Net Loss in Q4 Amid Generic Competition

  Despite strong sales of its blockbuster drug Dupixent, Sanofi on Thursday reported that its fourth-quarter 2023 operating income dropped 5% due to a weaker U.S. dollar, high expenses and generic competition.

  February 1, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Business

  Roche’s 2024 Strategy Seeks to Fight Low Growth with Pipeline Cuts, M&A

  The Swiss pharma on Thursday projected mid-single-digit sales growth for 2024, culling eight assets and looking to acquisitions and collaborations for de-risked assets with “significant potential.”

  February 1, 2024

   · 

  2 min read

   · 

  Kate Goodwin
• 

  Drug Development

  Neuroinflammation: The Natural Next Alzheimer’s Target?

  Biotech companies are exploring multiple targets in the fight against neuroinflammation. Experts say these projects could yield the next breakthrough in treating Alzheimer’s disease.

  February 1, 2024

   · 

  5 min read

   · 

  Heather McKenzie
• 

  Business

  Daiichi Sankyo Again Raises Enhertu Sales Forecast Driven by Non-US Growth

  Buoyed by its strong performance outside of the U.S. market, Daiichi Sankyo on Wednesday again raised its sales expectations for the blockbuster antibody-drug conjugate.

  February 1, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Policy

  FDA Commissioner Says Adcomm Reform, Funding and AI on Agency’s Agenda

  During a Wednesday webinar, FDA Commissioner Robert Califf said the agency is working on “systemic” changes to its advisory committee process.

  February 1, 2024

   · 

  2 min read

   · 

  Tyler Patchen
• Sai Life Sciences augments DMPK capabilities to ace large-scale collaborations

  To offer global big pharma clients cutting-edge, end-to-end drug metabolism and pharmacokinetics services, Sai Life Sciences, a global Contract Research, Development & Manufacturing Organization, has expanded its DMPK capabilities.

  February 1, 2024

   · 

  3 min read
• Drug Development

  Bio-Thera Solutions Announces Initiation of Phase IB / IIA Clinical Trial for BAT6026, a Monoclonal Antibody Targeting OX40, in Patients with Moderate to Severe Atopic Dermatitis

  Bio-Thera Solutions announced that dosing has begun in Phase IA/IIB clinical trial to study efficacy and safety of BAT6026 in patients with moderate to severe atopic dermatitis.

  February 1, 2024

   · 

  3 min read